These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20923042)

  • 1. Metabolic effects of hormone deprivation therapy: weighing the evidence.
    Van Londen GJ; Lembersky BC
    Oncology (Williston Park); 2010 Aug; 24(9):846-7. PubMed ID: 20923042
    [No Abstract]   [Full Text] [Related]  

  • 2. Considering metabolic effects when making breast cancer treatment decisions.
    Ligibel JA
    Oncology (Williston Park); 2010 Aug; 24(9):844-6. PubMed ID: 20923041
    [No Abstract]   [Full Text] [Related]  

  • 3. Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
    Dalla Volta A; Mazziotti G; Maffezzoni F; Grisanti S; Palumbo C; Pedersini R; Maroldi R; Berruti A
    J Clin Oncol; 2020 Oct; 38(29):3363-3366. PubMed ID: 32603244
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment effect of breast cancer and prostate cancer on bone].
    Varsavsky M; Guadalix Iglesias S
    Med Clin (Barc); 2013 Feb; 140(4):164-8. PubMed ID: 22841464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.
    Redig AJ; Munshi HG
    Oncology (Williston Park); 2010 Aug; 24(9):839-44. PubMed ID: 20923040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-aromatase acting drugs].
    Diedrich K
    Krankenpfl J; 2005; 43(4-6):150-1. PubMed ID: 16171094
    [No Abstract]   [Full Text] [Related]  

  • 7. Obesity and endocrine therapy: host factors and breast cancer outcome.
    Goodwin PJ
    Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant endocrine therapy for breast cancer.
    Rao RD; Cobleigh MA
    Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weighing up the risks and benefits of androgen deprivation therapy.
    Rees J
    Practitioner; 2014 May; 258(1771):5. PubMed ID: 25055405
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gynecomastia in patients with prostate cancer: update on treatment options.
    Autorino R; Perdonà S; D'Armiento M; De Sio M; Damiano R; Cosentino L; Di Lorenzo G
    Prostate Cancer Prostatic Dis; 2006; 9(2):109-14. PubMed ID: 16432533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic breast cancer.
    Stevanovic A; Lee P; Wilcken N
    Aust Fam Physician; 2006 May; 35(5):309-12. PubMed ID: 16680209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply to K.I. Pritchard.
    Fontein DB; van de Velde CJ;
    J Clin Oncol; 2013 Dec; 31(35):4477-9. PubMed ID: 24190123
    [No Abstract]   [Full Text] [Related]  

  • 15. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Information Concerning Endocrine Therapy and Adherence of Patients with Breast and Prostate Cancer.
    Linke B; Liebl P; Marten D; Stoll C; Jung B; Wuensch P; Huebner J
    Clin Oncol (R Coll Radiol); 2015 Aug; 27(8):482-3. PubMed ID: 25869258
    [No Abstract]   [Full Text] [Related]  

  • 17. The importance of nonpharmacogenetic factors in endocrine therapy.
    McCowan C; Thompson AM
    Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
    Wheler J; Johnson M; Seidman A
    Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to long-term adjuvant hormonal therapy for breast cancer.
    Gotay C; Dunn J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.